Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
- Pharm Res. 2016 Aug;33(8):2025-32. doi: 10.1007/s11095-016-1940-2.
- 1. Department of Physics, King's College London, Strand, London, WC2R 2LS, UK.
- 2. Department of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, Lambeth Wing, London, SE1 7EH, UK.
- 3. School of Medicine, King's College London, London, SE5 9RS, UK.
- 4. Department of Ophthalmology, King's College Hospital, London, SE5 9RS, UK.
- 5. Department of Physics, King's College London, Strand, London, WC2R 2LS, UK. [email protected].
Purpose: To measure the hydrodynamic radii of intravitreal anti-VEGF drugs ranibizumab, aflibercept and bevacizumab with μs time-resolved phosphorescence anisotropy.
Methods: Ruthenium-based dye Ru(bpy)2(mcbpy - O - Su - ester)(PF6)2, whose lifetime of several hundred nanoseconds is comparable to the rotational correlation time of these drugs in buffer, was used as a label. The hydrodynamic radii were calculated from the rotational correlation times of the Ru(bpy)2(mcbpy - O - Su - ester)(PF6)2-labelled drugs obtained with time-resolved phosphorescence anisotropy measurements in buffer/glycerol solutions of varying viscosity.
Results: The measured radii of 2.76±0.04 nm for ranibizumab, 3.70±0.03 nm for aflibercept and 4.58±0.01 nm for bevacizumab agree with calculations based on molecular weight and Other experimental measurements.
Conclusions: Time-resolved phosphorescence anisotropy is a relatively simple and straightforward method that allows experimental measurement of the hydrodynamic radius of individual proteins, and is superior to theoretical calculations which cannot give the required accuracy for a particular protein.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Fluorescent DyeResearch Areas: Cancer